Welcome to our dedicated page for Biolife Solutions SEC filings (Ticker: BLFS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The BioLife Solutions, Inc. (NASDAQ: BLFS) SEC filings page on Stock Titan provides access to the company’s official regulatory documents filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on BioLife’s activities as a developer and supplier of cell processing tools and services and bioproduction products and services for the cell and gene therapy (CGT) and broader biopharma markets.
Through periodic reports such as the Form 10-K annual report and Form 10-Q quarterly reports, investors can review disclosures on BioLife’s Cell Processing, Cold Chain, and Thawing product areas, its focus on biopreservation media and related tools, and the financial impact of divestitures and strategic transactions. These filings also describe the company’s use of GAAP and non-GAAP metrics, its presentation of discontinued operations related to divested subsidiaries, and other elements of its financial reporting framework.
Current reports on Form 8-K highlight specific material events, including quarterly earnings announcements, investor presentations, and the sale of its evo cold chain logistics subsidiary. Proxy materials such as the definitive proxy statement (DEF 14A) provide insight into corporate governance, board composition, executive compensation proposals, and matters submitted to stockholder votes at the annual meeting.
On Stock Titan, each new BioLife filing is captured from EDGAR and paired with AI-powered summaries that explain the key points in clear language. Users can quickly scan annual reports (Form 10-K), quarterly reports (Form 10-Q), and current reports (Form 8-K) to understand changes in BioLife’s cell processing business, portfolio evolution, and governance decisions. The filings page also surfaces information relevant to topics such as equity awards and compensation policies discussed in proxy statements, helping investors interpret the regulatory record behind the BLFS stock.
BioLife Solutions Inc. executive Karen A. Foster sold 2,577 shares of common stock in an open-market transaction. The sale occurred at a weighted average price of $19.17 per share and was executed under a pre-arranged Rule 10b5-1(c) trading plan adopted effective December 4, 2025.
Following this transaction on March 23, 2026, Foster directly held 108,758 shares of BioLife Solutions common stock. The shares were sold in multiple trades at prices ranging from $18.99 to $19.35, and detailed breakdowns are available upon request as noted in the filing.
The Vanguard Group filed Amendment No. 3 to a Schedule 13G/A reporting 0 shares of Common Stock, representing 0%, for BioLife Solutions Inc. The filing states an internal realignment on January 12, 2026 resulted in disaggregated reporting by subsidiaries; the amendment is signed on March 26, 2026.
BioLife Solutions Inc. President and CEO Roderick De Greef had 11,101 shares of Common Stock withheld to cover taxes on restricted stock units that vested. These shares were delivered back to the company as a tax-withholding disposition, not sold on the open market. Following this transaction, he directly holds 733,746 shares of BioLife Solutions common stock.
BioLife Solutions Inc. reported an insider tax-withholding transaction by Chief Marketing Officer Todd Berard. On the release of restricted stock units, 1,879 shares of common stock were withheld by the company to cover his tax obligations. After this non-market disposition, Berard directly holds 164,061 shares of BioLife Solutions common stock.
BIOLIFE SOLUTIONS INC Chief Technology Officer Sean Werner reported a routine tax-related share disposition. On the release of restricted stock units, the company withheld 1,681 shares of common stock at $19.12 per share to cover his tax obligations. After this withholding, Werner directly holds 48,251 shares of BIOLIFE SOLUTIONS common stock. This was not an open-market trade but an automatic share withholding mechanism tied to equity compensation.
BioLife Solutions Inc.'s Chief Financial Officer Troy Wichterman reported a routine tax-related share withholding tied to restricted stock vesting. On this Form 4, 3,749 shares of Common Stock were withheld at $19.12 per share to satisfy tax obligations that arose when restricted stock units were released.
These shares were not sold in the open market; they were retained by the company to cover taxes. After this transaction, Wichterman holds 216,900 shares of BioLife Solutions common stock directly, indicating he retains a substantial equity position following the RSU vesting event.
BioLife Solutions Inc. Chief Human Resources Officer Sarah Aebersold reported a routine tax-related share disposition. On the release of restricted stock units, the company withheld 931 shares of common stock to cover her tax obligations at $19.12 per share. After this withholding, she directly owns 92,429 shares. This was not an open-market sale but a standard mechanism tied to equity compensation vesting.
BioLife Solutions executive Karen A. Foster had shares withheld to cover taxes on equity compensation. On the release of restricted stock units, the company withheld 1,907 shares of Common Stock at a value of $19.12 per share to satisfy her tax obligations. After this tax-withholding disposition, she holds 111,335 shares of BioLife Solutions Common Stock directly.
BioLife Solutions EVP & Chief Scientific Officer Mathew Aby J. reported a routine tax-related share disposition. On the release of restricted stock units, 2,255 shares of common stock were withheld by the company at $19.12 per share to cover his tax obligations. After this withholding, he continues to directly own 390,682 shares of BioLife Solutions common stock, indicating that only a small portion of his overall holdings was affected and that this was not an open-market sale.
BLFS affiliate filed a Form 144 reporting the proposed sale of 2,577 shares of Common Stock via exercise of stock options. The filing also lists recent 10b5-1 cash sales by Karen Foster on 03/05/2026 (96,923 shares), 03/09/2026 (500 shares), 03/03/2026 (418 shares), and 01/06/2026 (335 shares) with proceeds shown alongside each trade.